Manu Robertson 11/9/20 1:44 PM 6 min read

Coronavirus Herd Immunity Likely Hard to Achieve

In an attempt to help the nation return to a sense of normalcy amidst the coronavirus pandemic, some organizations are advocating for individuals to take a “focused protection” approach to address COVID-19.

With this approach, people who are healthy, young, and at low risk of dying from the coronavirus are encouraged to gather and resume their normal routines in order to contract COVID, recover, and build herd immunity.

Although this plan might sound good in theory, the idea that developing herd immunity will help end the coronavirus pandemic is flawed.

For one, herd immunity is difficult to achieve, and even those who recover from COVID-19 might experience severe symptoms. The core tenet of the focused protection plan relies on the idea that people who contract COVID-19 will develop antibodies that offer long-lasting immunity from the virus. However, research shows that this is not the case.

A study conducted by Imperial College London and polling organization Ipsos Mori found that the number of people with COVID-19 antibodies “decreased by 26.5% between June 20 and September 28” [1]. Whereas roughly 6% had antibodies in June, only 4.4% had antibodies in September.

Even though young individuals lose antibodies at a slower rate than those who are older, the evidence is still clear: COVID-19 antibodies will not lead to widespread, long-term herd immunity [1].

Furthermore, there are far too many people who are immunocompromised or otherwise at risk for this plan to work effectively.

According to Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, a focused protection plan would lead to thousands of unnecessary deaths noting, “by the time you get to herd immunity you will have killed a lot of people that would have been avoidable” [2].

Pushing for herd immunity rather than continuing to practice social distancing, mask-wearing, and other preventative measures to combat COVID-19, will only lead to more deaths and more hospitals being forced to close as they deal with bottlenecking and scrounge for PPE.

Although there are people who continue to believe that herd immunity will provide the solution to the coronavirus pandemic, the statistics are clear: COVID is not ending anytime soon.

As positive COVID-19 cases continue to rise in the United States, protecting hospitals and healthcare workers must become a priority.

The SCONE™ is one way to help.

How the SCONE™ protects hospitals and healthcare workers

The SCONE™ is a device that can help hospitals and healthcare workers stay safe during the ongoing coronavirus pandemic. Using negative-pressure technology, the SCONE™ is able to clear infectious aerosols and droplets within minutes, providing an extra, active layer of protection for health care workers and reducing the need for PPE.

This makes a huge difference when it comes to keeping hospitals open and keeping physicians, nurses, and other healthcare professionals safe as they provide patient care.

Since the start of the pandemic, the increased need for resources like PPE and ventilators coupled with a lack of revenue due to postponed elective procedures has caused dozens of hospitals to file for bankruptcy or close their doors altogether. As the United States heads into a second wave of COVID-19, more hospitals will follow suit unless there is a solution in place to solve this issue.

By reducing the need for PPE and PPE changes and helping maximize throughput, the SCONE™ will help alleviate the financial burden hospitals are facing during this pandemic.

The SCONE™ will also help protect healthcare workers, who are at high risk for COVID-19. Healthcare workers who use this device will have additional protection from infectious droplets and aerosols as they complete procedures like intubations, bronchoscopies, and other procedures that put them at risk.

Because herd immunity is not going to be the solution to the coronavirus pandemic, it is important to support hospitals and healthcare workers as the United States faces another wave of COVID-19. The SCONE™ can help.


SCONE™ has been authorized by the FDA for Emergency Use. Connect with us to learn more.Let's Connect




Manu Robertson

Manu has been in healthcare sales and management for over 13 years. He began his sales career as the third employee for a start-up company selling dental consulting and education with a focus in using software as a service (SAAS). After working as a territory rep for 7 years he moved into a management role where managed a team of 17 sales professionals and support staff. This start-up grew into SPEAR the largest dental education and consulting company in the world. Most recently Manu has recruited, educated, and managed distributors throughout the U.S. selling regenerative medicine. Manu uses his SAAS business acumen to bring his clients success at the enterprise level. He also holds a Master’s of Science degree in Organic Chemistry from Northern Arizona University.